title: AM-111 prevents hearing loss from semicircular canal injury in otitis media.
abstract: OBJECTIVE
  Iatrogenic semicircular canal (SC) transection during mastoidectomy for chronic otitis media often leads to profound hearing loss. AM-111, an apoptosis inhibitor, has been shown to mitigate hearing loss resulting from a variety of inner ear injuries. The goal of this study was to determine if round window application of AM-111 following SC transection in the presence of Pseudomonas aeruginosa otitis media (PA-OM) may reduce the associated hearing loss.
  
  
  METHODS
  Prospective, randomized, controlled study in an animal model.
  
  
  METHODS
  PA-OM was induced bilaterally in 34 guinea pigs. After 3 days, both bullae were opened and the lateral SC of one ear was transected. AM-111 or vehicle was applied topically to the round window of the ear that had undergone SC transection. Hearing was assessed with auditory brainstem responses.
  
  
  RESULTS
  The mean change in hearing thresholds was significantly less in transected ears treated with AM-111 than those receiving vehicle alone when testing with clicks (22.1 dB vs. 35.0 dB; P = .019) and at 4kHz (11.3 dB vs. 40.0 dB; P = .021). A similar trend was shown with 16 kHz tone pips (27.7 dB vs. 41.1 dB; P = .119).
  
  
  CONCLUSIONS
  AM-111 prevents hearing loss from SC transection in the guinea pig model of PA-OM.
authors.affiliation: Department of Otolaryngology, University of Florida, Gainesville, Florida 32610-0264, USA.
authors.forename: Tyler C
authors.initials: TC
authors.lastname: Grindal
authors.forename: Edith M
authors.initials: EM
authors.lastname: Sampson
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Antonelli
mesh_terms: D000287:Administration, Topical; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D006168:Guinea Pigs; D034381:Hearing Loss / Q000209:etiology / Q000517:prevention & control*; D010033:Otitis Media / Q000150:complications*; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D011552:Pseudomonas Infections / Q000150:complications; D011550:Pseudomonas aeruginosa; D011897:Random Allocation; D012665:Semicircular Canals / Q000293:injuries*
chemical_list: D010455:Peptides; C478085:D-JNKI-1